Vertex Kidney Disease Drug Shows Positive Trial Results
Vertex’s Promising IgA Nephropathy Drug Shows Significant Results in Phase 3 Trial In a significant advancement for the treatment of IgA nephropathy, Vertex Pharmaceuticals announced Monday that a newly acquired drug has demonstrated a 50% reduction in a key biomarker associated with the kidney disease. The positive results, stemming from a Phase 3 clinical trial, … Read more